9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS)
Key Takeaways
- IARC Groups 1, 2A, 2B, and 3 express the strength of evidence that an agent is a human carcinogen; Group 4 (probably not carcinogenic to humans) has been retired and is no longer used.
- EPA 2005 Guidelines descriptors are carcinogenic to humans, likely to be carcinogenic to humans, suggestive evidence of carcinogenic potential, inadequate information to assess carcinogenic potential, and not likely to be carcinogenic to humans.
- Under EPA 2005, a mutagenic (DNA-reactive) mode of action defaults to linear low-dose extrapolation from a point of departure; a well-supported nonlinear MOA may support a nonlinear approach.
- GHS Category 1A is known human carcinogenicity based largely on human evidence; 1B is presumed, based largely on animal evidence; Category 2 is suspected.
- NTP Report on Carcinogens uses two listings—known to be a human carcinogen and reasonably anticipated to be a human carcinogen—and a non-listing is not a safety conclusion.
Why classification is still a hazard step
Cancer classification schemes sit inside hazard identification. They answer how strong the evidence is that an agent can cause cancer in humans (or, for GHS, how the evidence should be labeled for communication). They do not, by themselves, set a workplace limit, a cancer slope factor, or a drinking-water concentration. Those numbers require dose–response and exposure. Independent OpenExamPrep teaching in this section covers IARC, EPA’s 2005 Guidelines for Carcinogen Risk Assessment, GHS, and the NTP Report on Carcinogens (RoC) so you can tell the schemes apart on a DABT item. It is not an IARC, EPA, OSHA, or NTP product and does not claim official approval, review, or partnership with those bodies or with ABT.
A second examination skill is restraint on named chemicals. IARC evaluations are living documents. Use well-established examples you can defend—benzene and vinyl chloride are both IARC Group 1—or speak generically. Do not invent a current Group for an agent whose Monograph you have not checked.
IARC Monograph groups
The International Agency for Research on Cancer evaluates agents (chemicals, mixtures, occupations, physical agents, biological agents) in Monographs. The evaluation is a hazard conclusion about cancer, not a quantitative risk estimate and not a recommendation to ban or permit use.
Current groups after the 2019 Preamble update:
- Group 1 — Carcinogenic to humans. Sufficient evidence in humans, or a combination of sufficient evidence in animals plus strong mechanistic evidence in exposed humans, depending on the Preamble’s integration rules.
- Group 2A — Probably carcinogenic to humans. Typically limited evidence in humans and sufficient evidence in animals, or other specified combinations including strong mechanistic data.
- Group 2B — Possibly carcinogenic to humans. Typically limited human evidence or sufficient animal evidence that does not meet 2A, among other allowed combinations.
- Group 3 — Not classifiable as to its carcinogenicity to humans. Evidence is inadequate in humans and inadequate or limited in animals, or the data do not fit a higher group. Group 3 is not a certificate of non-carcinogenicity.
Group 4 — Probably not carcinogenic to humans — has been retired. It is no longer part of the IARC scheme. Historically it was used extremely rarely (caprolactam was the classic occupant before later re-evaluation). If an item still lists Group 4 as a current option, the current answer is that the group is not used.
Benzene (leukemia, including acute myeloid leukemia, with bone-marrow toxicity as the organ story) and vinyl chloride (hepatic angiosarcoma as the highly specific pairing) are durable Group 1 teaching examples. Specificity in the Bradford Hill sense is unusually strong for vinyl chloride and angiosarcoma; benzene’s hematopoietic story is broader but equally well established as a human cancer hazard.
IARC does not issue potency (no slope factor, no “safe dose”). Two Group 1 agents can differ by orders of magnitude in carcinogenic potency. Classification strength is not the same variable as potency.
EPA 2005 Guidelines descriptors
The U.S. Environmental Protection Agency’s Guidelines for Carcinogen Risk Assessment (2005) describe weight-of-evidence descriptors that can be applied to a specified route and, when data allow, to all routes. The five descriptors are:
- Carcinogenic to humans
- Likely to be carcinogenic to humans
- Suggestive evidence of carcinogenic potential
- Inadequate information to assess carcinogenic potential
- Not likely to be carcinogenic to humans
Descriptors can be qualified by route. An agent may be “likely” by inhalation and “not likely” by the oral route if the database truly splits that way. “Not likely” is an affirmative WoE conclusion, not a missing-data bin; missing data belong under inadequate information.
EPA’s guidelines also include a mode of action (MOA) framework that changes how dose–response is done after the hazard descriptor is chosen:
- Mutagenic (DNA-reactive) MOA. The default is linear extrapolation from a point of departure (POD) (often a BMD or LED associated with extra risk) down through the origin. The public-health rationale is that a single mutational event can contribute to cancer and that endogenous processes do not provide a practical threshold you can defend for regulation.
- Nonlinear MOA. If a well-supported MOA is cytotoxicity with regenerative proliferation, or another threshold-type key event, EPA may use a nonlinear (reference-dose-like or margin-of-exposure) approach below the POD.
- Unknown or mixed MOA. Linear methods are often retained as a health-protective default when a mutagenic MOA cannot be reasonably ruled out.
Do not confuse the descriptor (words about evidence strength) with the extrapolation method (linear versus nonlinear). A “likely” carcinogen with a mutagenic MOA still uses linear low-dose methods in the default EPA logic. IARC’s Group number does not dictate EPA’s math.
GHS carcinogen categories
The UN Globally Harmonized System (GHS) classifies carcinogens for hazard communication (labels and safety data sheets):
- Category 1 — Known or presumed human carcinogens.
- 1A — Known, based largely on human evidence.
- 1B — Presumed, based largely on animal evidence.
- Category 2 — Suspected human carcinogens, when human and animal evidence is not sufficiently convincing for Category 1.
GHS is a labeling scheme with specified criteria, not a cancer-potency assessment. A 1B label can trigger the same communication duties as 1A in many jurisdictions even though the evidence base differs. Do not translate GHS 1B as “IARC Group 3” or as EPA “not likely.” The mapping is many-to-many, not one-to-one.
NTP Report on Carcinogens
The U.S. National Toxicology Program Report on Carcinogens is a congressionally mandated listing of substances that are:
- Known to be a human carcinogen, or
- Reasonably anticipated to be a human carcinogen.
“Known” requires sufficient human evidence (or specified equivalent integration). “Reasonably anticipated” typically rests on sufficient animal evidence or a combination of limited human evidence and other data, depending on the listing criteria in force for that RoC edition. Absence from the RoC is not a conclusion of safety. Many agents have never been reviewed. Benzene and vinyl chloride are in the “known” teaching set alongside their IARC Group 1 evaluations; use them as examples of concordant high-confidence listings, not as a claim that every scheme always agrees on every chemical.
Agencies can disagree on agents that are still under scientific debate. That disagreement is a feature of different evidence rules, different default assumptions, and different jobs (research evaluation versus regulation versus labeling). It is not proof that one scheme is “the real IARC.” On an item, name the scheme the stem asks for.
| Scheme | Highest-confidence cancer hazard | Intermediate | Inadequate / lowest |
|---|---|---|---|
| IARC Monographs | Group 1 (carcinogenic to humans) | Group 2A (probably), Group 2B (possibly) | Group 3 (not classifiable); Group 4 retired |
| EPA 2005 Guidelines | Carcinogenic to humans | Likely; suggestive evidence | Inadequate information; not likely |
| GHS | Category 1A (known, human evidence) | Category 1B (presumed, animal evidence) | Category 2 (suspected); unclassified if criteria not met |
| NTP RoC | Known to be a human carcinogen | Reasonably anticipated to be a human carcinogen | Not listed (often never reviewed—not a safety finding) |
Read the table as related vocabularies, not as a conversion chart. IARC 2B is not identical to EPA “suggestive.” GHS 1B is not identical to NTP “reasonably anticipated,” even when they often land on the same famous chemicals.
Scenario
A stem gives sufficient human epidemiologic evidence of leukemia in benzene-exposed workers, supporting animal data, and a DNA-reactive metabolite story. IARC Group 1, EPA carcinogenic to humans, GHS 1A, and NTP known are the concordant high-confidence labels. EPA’s linear default still applies for low-dose extrapolation if the MOA is treated as mutagenic. None of those labels is a PEL or an IRIS slope factor by itself.
A second stem has only limited human evidence and sufficient animal tumors, without strong human mechanistic data. IARC may land in 2A or 2B depending on the full Preamble integration; EPA may land on likely or suggestive; GHS may be 1B or 2. Forcing all four schemes onto one letter is the error.
A third stem asks whether Group 4 means “proven safe.” The current answer is that Group 4 is retired, and even historically it was not a general “safe chemical” bin.
Traps
- Treating Group 3 or “inadequate information” as proof of non-carcinogenicity.
- Using Group 4 as if it were still an active IARC category.
- Equating IARC group, EPA descriptor, GHS category, and NTP listing as interchangeable codes.
- Letting an IARC group choose linear versus nonlinear EPA math.
- Inventing a current IARC Group for a chemical whose Monograph you have not verified—stay with benzene, vinyl chloride, or generic wording.
Which statement correctly describes current IARC Monograph groups?
Under the EPA 2005 Guidelines for Carcinogen Risk Assessment, how does mode of action change low-dose extrapolation?
How do GHS carcinogen Categories 1A and 1B differ?